Arrigo F. Cicero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4486728/publications.pdf

Version: 2024-02-01

564 papers 17,726 citations

67 h-index 98 g-index

582 all docs 582 docs citations

times ranked

582

19675 citing authors

#	Article	IF	CITATIONS
1	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	1.3	330
2	Immune modulation by curcumin: The role of interleukin-10. Critical Reviews in Food Science and Nutrition, 2019, 59, 89-101.	5.4	259
3	Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacological Research, 2016, 107, 234-242.	3.1	253
4	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	2.6	238
5	Rice Bran Oil and ?-Oryzanol in the Treatment of Hyperlipoproteinaemias and Other Conditions. Phytotherapy Research, 2001, 15, 277-289.	2.8	227
6	Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. British Journal of Pharmacology, 2017, 174, 1378-1394.	2.7	219
7	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	1.2	216
8	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.4	206
9	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	1.3	177
10	Berberine and Its Role in Chronic Disease. Advances in Experimental Medicine and Biology, 2016, 928, 27-45.	0.8	171
11	Curcumin: A naturally occurring autophagy modulator. Journal of Cellular Physiology, 2019, 234, 5643-5654.	2.0	167
12	Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. Nutrients, 2017, 9, 395.	1.7	166
13	PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports, 2018, 8, 2267.	1.6	166
14	Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition, 2016, 32, 1179-1192.	1.1	157
15	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opinion on Biological Therapy, 2012, 12, 1113-1124.	1.4	150
16	Bioactive Peptides in Cereals and Legumes: Agronomical, Biochemical and Clinical Aspects. International Journal of Molecular Sciences, 2014, 15, 21120-21135.	1.8	141
17	Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis. Journal of Hypertension, 2014, 32, 57-64.	0.3	141
18	Matrix Metalloproteinase-2 and -9 Levels in Obese Patients. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 219-224.	1.7	137

#	Article	IF	CITATIONS
19	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical Therapeutics, 2004, 26, 744-754.	1.1	136
20	Lepidium meyenii Walp. improves sexual behaviour in male rats independently from its action on spontaneous locomotor activity. Journal of Ethnopharmacology, 2001, 75, 225-229.	2.0	128
21	Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. Journal of Human Hypertension, 2011, 25, 425-436.	1.0	119
22	Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opinion on Drug Safety, 2019, 18, 261-271.	1.0	117
23	Matrix Metalloproteinase-2, -9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Hypertension. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 227-231.	1.7	116
24	State of the art paper Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Archives of Medical Science, 2012, 5, 794-804.	0.4	115
25	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients, 2018, 10, 1153.	1.7	115
26	Evaluation ofÂmetalloproteinase 2Âand 9Âlevels andÂtheirÂinhibitors inÂdiabetic andÂhealthy subjects. Diabetes and Metabolism, 2007, 33, 129-134.	1.4	114
27	Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food and Function, 2017, 8, 2076-2088.	2.1	114
28	Exenatide Versus Glibenclamide in Patients with Diabetes. Diabetes Technology and Therapeutics, 2010, 12, 233-240.	2.4	113
29	Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet on Cardiometabolic Factors: A Multi-Center, Cross-Sectional, Clinical Study. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 389-394.	1.0	110
30	Role of phytochemicals in the management of metabolic syndrome. Phytomedicine, 2016, 23, 1134-1144.	2.3	109
31	The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clinical Therapeutics, 2003, 25, 1429-1439.	1.1	108
32	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition, 2020, 39, 1742-1752.	2.3	106
33	Natural approaches in metabolic syndrome management. Archives of Medical Science, 2018, 14, 422-441.	0.4	103
34	Long-Term Follow-Up of Patients Treated for Chronic Headache with Analgesic Overuse. Cephalalgia, 2001, 21, 878-883.	1.8	102
35	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism: Clinical and Experimental, 2010, 59, 887-895.	1.5	102
36	Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. European Journal of Nutrition, 2020, 59, 477-483.	1.8	102

#	Article	IF	Citations
37	Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management. Current Vascular Pharmacology, 2009, 7, 330-337.	0.8	101
38	Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacological Research, 2018, 134, 51-60.	3.1	98
39	Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents. Arzneimittelforschung, 2007, 57, 26-30.	0.5	97
40	Do the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials. American Journal of Hypertension, 2013, 26, 442-449.	1.0	96
41	Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. International Journal of Cardiology, 2018, 261, 183-188.	0.8	95
42	State of the art paper Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. Archives of Medical Science, 2013, 5, 944-952.	0.4	94
43	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Critical Reviews in Food Science and Nutrition, 2019, 59, 1605-1618.	5.4	94
44	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq(0.0 rgBT 1.0	/Oygrlock 10
45	Subjective effects of <i>Lepidium meyenii < i> (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Andrologia, 2009, 41, 95-99.</i>	1.0	91
46	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 143, 1-16.	3.1	90
47	Nutraceuticals with a clinically detectable blood pressureâ€lowering effect: a review of available randomized clinical trials and their metaâ€analyses. British Journal of Clinical Pharmacology, 2017, 83, 163-171.	1.1	88
48	Panax notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. Phytotherapy Research, 2003, 17, 174-178.	2.8	87
49	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. Current Pharmaceutical Design, 2018, 24, 239-258.	0.9	87
50	Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs, 2019, 79, 751-766.	4.9	86
51	Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism: Clinical and Experimental, 2016, 65, 1664-1678.	1.5	85
52	Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 375-383.	0.7	84
53	Changes in LDL Fatty Acid Composition as a Response to Olive Oil Treatment Are Inversely Related to Lipid Oxidative Damage: The EUROLIVE Study. Journal of the American College of Nutrition, 2008, 27, 314-320.	1.1	84
54	A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atherosclerosis Supplements, 2017, 24, 1-15.	1.2	83

#	Article	IF	CITATIONS
55	Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clinical Therapeutics, 2004, 26, 1228-1236.	1.1	79
56	Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Scientific Reports, 2018, 8, 11529.	1.6	78
57	Comparison of fluvastatin + fenofibrate combination therapyand fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical Therapeutics, 2004, 26, 1599-1607.	1.1	77
58	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Research and Clinical Practice, 2005, 69, 5-13.	1.1	77
59	Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis FactorALPHA Hypertension Research, 2006, 29, 849-856.	1.5	77
60	Regulatory effects of berberine on microRNome in Cancer and other conditions. Critical Reviews in Oncology/Hematology, 2017, 116, 147-158.	2.0	77
61	Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. Current Medicinal Chemistry, 2016, 23, 1460-1476.	1.2	76
62	Cocoa Bioactive Compounds: Significance and Potential for the Maintenance of Skin Health. Nutrients, 2014, 6, 3202-3213.	1.7	75
63	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	2.3	75
64	Different Effect of Psyllium and Guar Dietary Supplementation on Blood Pressure Control in Hypertensive Overweight Patients: A Six-Month, Randomized Clinical Trial. Clinical and Experimental Hypertension, 2007, 29, 383-394.	0.5	72
65	High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine, 2017, 37, 38-42.	1.0	70
66	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.3	70
67	Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 261-268.	0.7	69
68	Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Archivio Italiano Di Urologia Andrologia, 2019, 91, .	0.4	69
69	Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents Metformin and its clinical use: new insights for an old drug in clinical practice. Archives of Medical Science, 2012, 5, 907-917.	0.4	68
70	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal, 2017, 50, 1700711.	3.1	68
71	Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. European Journal of Nutrition, 2021, 60, 655-663.	1.8	67
72	Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia, 2002, 34, 177-179.	1.0	66

#	Article	IF	CITATIONS
73	Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial. Clinical Therapeutics, 2006, 28, 679-688.	1.1	66
74	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association, 2017, 6, .	1.6	66
75	Can Phyllanthus niruri Affect the Efficacy of Extracorporeal Shock Wave Lithotripsy for Renal Stones? A Randomized, Prospective, Long-Term Study. Journal of Urology, 2006, 176, 1020-1022.	0.2	65
76	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutrition Research, 2013, 33, 622-628.	1.3	65
77	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, \hat{l}^2 -cell function and insulin resistance in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2012, 98, 51-60.	1.1	64
78	Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003121.	3.9	64
79	Coenzyme Q10: Clinical Applications in Cardiovascular Diseases. Antioxidants, 2020, 9, 341.	2.2	64
80	Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, Obesity and Metabolism, 2005, 7, 47-55.	2.2	63
81	Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. Annals of Medicine, 2018, 50, 1-6.	1.5	63
82	Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights. Marine Drugs, 2020, 18, 239.	2.2	63
83	An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vascular Health and Risk Management, 2017, Volume 13, 23-28.	1.0	62
84	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 47-54.	0.2	60
85	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition, 2018, 58, 2549-2556.	5.4	60
86	Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opinion on Drug Safety, 2012, 11, 753-766.	1.0	58
87	Antidiabetic Properties of Berberine: From Cellular Pharmacology to Clinical Effects. Hospital Practice (1995), 2012, 40, 56-63.	0.5	58
88	Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vascular Health and Risk Management, 2007, 3, 877-86.	1.0	58
89	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart and Vessels, 2007, 22, 361-370.	0.5	57
90	Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin. Hypertension Research, 2007, 30, 387-394.	1.5	56

#	Article	IF	Citations
91	Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension. Journal of Hypertension, 2019, 37, 728-731.	0.3	56
92	What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. Acta Diabetologica, 2004, 41, 91-98.	1.2	55
93	Need for Analgesics/drugs of Abuse: A Comparison Between Headache Patients and Addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia, 2006, 26, 187-193.	1.8	54
94	COVID-19-Related Quarantine Effect on Dietary Habits in a Northern Italian Rural Population: Data from the Brisighella Heart Study. Nutrients, 2021, 13, 309.	1.7	54
95	Botanicals and phytochemicals active on cognitive decline: The clinical evidence. Pharmacological Research, 2018, 130, 204-212.	3.1	53
96	A Randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT) Study. Nutrients, 2020, 12, 686.	1.7	53
97	Non-pharmacological control of plasma cholesterol levels. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, S1-S16.	1.1	52
98	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load. Journal of Clinical Lipidology, 2012, 6, 553-564.	0.6	52
99	Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. Annals of Medicine, 2017, 49, 275-282.	1.5	52
100	Omega 3 Polyunsaturated Fatty Acids Supplementation and Blood Pressure Levels in Hypertriglyceridemic Patients with Untreated Normal-High Blood Pressure and With or Without Metabolic Syndrome: A Retrospective Study. Clinical and Experimental Hypertension, 2010, 32, 137-144.	0.5	51
101	Hyperuricemia and cardiovascular disease risk. Expert Review of Cardiovascular Therapy, 2014, 12, 1219-1225.	0.6	51
102	Serum Uric Acid and Cardiometabolic Disease. Hypertension, 2017, 69, 1011-1013.	1.3	51
103	Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?. Current Atherosclerosis Reports, 2021, 23, 57.	2.0	51
104	Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data. Phytomedicine, 2016, 23, 1113-1118.	2.3	50
105	Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 9-25.	1.0	50
106	Relationship between serum zinc levels, thyroid hormones and thyroid volume following successful iodine supplementation. Hormones, 2010, 9, 263-268.	0.9	49
107	Berberine: A potential adjunct for the treatment of gastrointestinal cancers?. Journal of Cellular Biochemistry, 2018, 119, 9655-9663.	1.2	49
108	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.3	49

#	Article	lF	CITATIONS
109	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocrine Journal, 2010, 57, 777-786.	0.7	48
110	State of the art paper Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Archives of Medical Science, 2012, 5, 784-793.	0.4	48
111	Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Medical Principles and Practice, 2021, 30, 122-130.	1.1	48
112	Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Lithuania), 2021, 57, 58.	0.8	48
113	Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride. Hypertension Research, 2005, 28, 917-924.	1.5	47
114	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. European Journal of Pharmacology, 2011, 651, 240-250.	1.7	47
115	Vildagliptin Added to Metformin on \hat{l}^2 -Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients. Diabetes Technology and Therapeutics, 2012, 14, 475-484.	2.4	47
116	Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases. Nutrients, 2021, 13, 1697.	1.7	47
117	Effects of nâ€3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors, 2016, 42, 316-322.	2.6	47
118	Red Yeast Rice for Hypercholesterolemia. Methodist DeBakey Cardiovascular Journal, 2021, 15, 192.	0.5	47
119	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Annals of Hepatology, 2018, 17, 64-75.	0.6	46
120	The Role of Nutrition and Nutritional Supplements in Ocular Surface Diseases. Nutrients, 2020, 12, 952.	1.7	46
121	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340.	0.3	46
122	Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella Study. Internal and Emergency Medicine, 2015, 10, 25-31.	1.0	45
123	Protective effects of curcumin against aflatoxicosis: A comprehensive review. Journal of Cellular Physiology, 2018, 233, 3552-3577.	2.0	45
124	LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort. International Journal of Cardiology, 2018, 261, 204-208.	0.8	44
125	Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Archives of Gerontology and Geriatrics, 2004, 38, 201-212.	1.4	43
126	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal, 2007, 37, 79-86.	0.5	43

#	Article	IF	CITATIONS
127	25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women. Archives of Medical Science, 2012, 1, 47-52.	0.4	43
128	Nutraceuticals for blood pressure control. Annals of Medicine, 2015, 47, 447-456.	1.5	43
129	Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials. Current Pharmaceutical Design, 2017, 23, 2422-2427.	0.9	43
130	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	0.6	43
131	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. Journal of Hypertension, 2020, 38, 799-812.	0.3	43
132	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 187-195.	0.7	42
133	Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study. Molecular Nutrition and Food Research, 2017, 61, 1700373.	1.5	42
134	Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. European Journal of Internal Medicine, 2017, 37, 49-55.	1.0	42
135	The potential role of plant-derived natural products in improving arterial stiffness: A review of dietary intervention studies. Trends in Food Science and Technology, 2020, 99, 426-440.	7.8	42
136	Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot study. Complementary Therapies in Medicine, 2005, 13, 273-278.	1.3	41
137	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart and Vessels, 2009, 24, 204-210.	0.5	41
138	Resveratrol and cognitive decline: a clinician perspective. Archives of Medical Science, 2019, 15, 936-943.	0.4	41
139	Red Yeast Rice for Hypercholesterolemia. Journal of the American College of Cardiology, 2021, 77, 620-628.	1.2	41
140	Effects of phytochemicals on macrophage cholesterol efflux capacity: Impact on atherosclerosis. Phytotherapy Research, 2021, 35, 2854-2878.	2.8	41
141	Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertension Research, 2011, 34, 1035-1040.	1.5	40
142	The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. Current Hypertension Reports, 2017, 19, 95.	1.5	40
143	Headache Treatment Before and After the Consultation of a Specialized Centre: A Pharmacoepidemiology Study. Cephalalgia, 2004, 24, 356-362.	1.8	39
144	Immediate Improvement in Penile Hemodynamics after Cessation of Smoking: Previous Results. Urology, 2007, 69, 163-165.	0.5	39

#	Article	IF	CITATIONS
145	Oral Glucose Tolerance Test Effects on Endothelial Inflammation Markers in Healthy Subjects and Diabetic Patients. Hormone and Metabolic Research, 2010, 42, 8-13.	0.7	39
146	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2017, 75, 361-373.	2.6	39
147	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.4	39
148	Altilix \hat{A}^{\circledast} Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2019, 11, 2580.	1.7	39
149	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	1.6	39
150	Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes, Obesity and Metabolism, 2006, 8, 197-205.	2.2	38
151	Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clinical Lipidology, 2009, 4, 553-563.	0.4	38
152	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Current Medical Research and Opinion, 2009, 25, 607-615.	0.9	38
153	Middle-Term Dietary Supplementation with Red Yeast Rice Plus Coenzyme Q10 Improves Lipid Pattern, Endothelial Reactivity and Arterial Stiffness in Moderately Hypercholesterolemic Subjects. Annals of Nutrition and Metabolism, 2016, 68, 213-219.	1.0	38
154	Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12-month, double-blind, randomized clinical trial. Clinical Therapeutics, 2005, 27, 1383-1391.	1.1	37
155	Vascular Remodeling and Prothrombotic Markers in Subjects Affected by Familial Combined Hyperlipidemia and/or Metabolic Syndrome in Primary Prevention for Cardiovascular Disease. Endothelium: Journal of Endothelial Cell Research, 2007, 14, 193-198.	1.7	37
156	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Current Medical Research and Opinion, 2009, 25, 1973-1983.	0.9	37
157	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. European Journal of Internal Medicine, 2018, 53, 29-33.	1.0	37
158	Metabolic effect of berberine–silymarin association: A metaâ€analysis of randomized, doubleâ€blind, placeboâ€controlled clinical trials. Phytotherapy Research, 2019, 33, 862-870.	2.8	37
159	Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies. Drug Safety, 2020, 43, 727-736.	1.4	37
160	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	1.0	37
161	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertension Research, 2011, 34, 145-151.	1.5	36
162	Renin–angiotensin system at the crossroad of hypertension and hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 115-120.	1.1	36

#	Article	IF	Citations
163	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs, 2018, 78, 99-109.	4.9	36
164	Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opinion on Drug Safety, 2019, 18, 611-621.	1.0	36
165	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clinical and Investigative Medicine, 2009, 32, 124.	0.3	36
166	EFFECTS OF SIBERIAN GINSENG (ELEUTHEROCOCCUS SENTICOSUS MAXIM.) ON ELDERLY QUALITY OF LIFE: A RANDOMIZED CLINICAL TRIAL. Archives of Gerontology and Geriatrics, 2004, 38, 69-73.	1.4	35
167	Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. European Journal of Internal Medicine, 2015, 26, 255-258.	1.0	35
168	Dietary Intervention to Improve Blood Pressure Control: Beyond Salt Restriction. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 547-553.	1.0	35
169	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper from <i>the International Lipid Expert Panel</i> (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	2.9	35
170	Effects of a New Soy/ \hat{l}^2 -Sitosterol Supplement on Plasma Lipids in Moderately Hypercholesterolemic Subjects. Journal of the American Dietetic Association, 2002, 102, 1807-1811.	1.3	34
171	Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients. Internal Medicine, 2010, 49, 1717-1725.	0.3	34
172	Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism: Clinical and Experimental, 2011, 60, 421-429.	1.5	34
173	Nutraceuticals and Blood Pressure Control: Results from Clinical Trials and Meta-Analyses. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 203-213.	1.0	34
174	Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutrition and Metabolism, 2017, 14, 61.	1.3	34
175	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. Metabolites, 2020, 10, 392.	1.3	34
176	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221.	0.9	34
177	Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside. Current Vascular Pharmacology, 2014, 12, 565-571.	0.8	34
178	ORIGINAL ARTICLE: Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 565-579.	0.7	33
179	Psychosocial factors and metabolic parameters: Is there any association in elderly people? The Massa Lombarda Project. Aging and Mental Health, 2010, 14, 801-806.	1.5	33
180	Leisure-time physical activity and cardiovascular disease mortality. Journal of Cardiovascular Medicine, 2012, 13, 559-564.	0.6	33

#	Article	IF	Citations
181	ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. Journal of Lipid Research, 2013, 54, 238-243.	2.0	33
182	Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opinion on Drug Safety, 2014, 13, 1023-1030.	1.0	33
183	Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants, 2020, 9, 1011.	2.2	33
184	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opinion on Pharmacotherapy, 2010, 11, 1971-1982.	0.9	32
185	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 972-973.	13.9	32
186	Orally administered Panax notoginseng influence on rat spontaneous behaviour. Journal of Ethnopharmacology, 2000, 73, 387-391.	2.0	31
187	Metalloproteinase-2 and -9 in Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes. Endothelium: Journal of Endothelial Cell Research, 2007, 14, 45-51.	1.7	31
188	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutrition Research Reviews, 2020, 33, 155-179.	2.1	31
189	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082.	1.5	31
190	Dietary interventions in blood pressure lowering: current evidence in 2020. Kardiologia Polska, 2020, 78, 659-666.	0.3	31
191	Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina (Lithuania), 2022, 58, 299.	0.8	31
192	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clinical Therapeutics, 2003, 25, 2006-2021.	1.1	30
193	Comparison between orlistat plus <scp>l</scp> â€carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundamental and Clinical Pharmacology, 2011, 25, 642-651.	1.0	30
194	Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load. Hormone and Metabolic Research, 2011, 43, 505-512.	0.7	30
195	Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin. Internal Medicine, 2013, 52, 2179-2187.	0.3	30
196	Uricaemia and ejection fraction in elderly heart failure outpatients. European Journal of Clinical Investigation, 2014, 44, 573-577.	1.7	30
197	Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. Archives of Medical Science, 2016, 3, 507-512.	0.4	30
198	Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 552-563.	1.1	30

#	Article	IF	Citations
199	Uric Acid and Hypertension: Prognostic Role and Guide for Treatment. Journal of Clinical Medicine, 2021, 10, 448.	1.0	30
200	Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence. International Journal of Molecular Sciences, 2021, 22, 12920.	1.8	30
201	Effects of long chain ï‰-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opinion on Pharmacotherapy, 2009, 10, 1239-1247.	0.9	29
202	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvascular Research, 2010, 80, 110-115.	1.1	29
203	Threeâ€arm, placeboâ€controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects. Phytotherapy Research, 2019, 33, 2094-2101.	2.8	29
204	Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety, 2022, 21, 9-20.	1.0	29
205	Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes, Nutrition & Metabolism, 2004, 17, 222-9.	0.4	29
206	Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension. Journal of Cardiovascular Pharmacology, 2005, 45, 599-604.	0.8	28
207	From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study. Clinical Lipidology, 2011, 6, 269-276.	0.4	28
208	Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Cl \tilde{A} nica E Investigaci \tilde{A} 3n En Arteriosclerosis, 2016, 28, 178-187.	0.4	28
209	Arterial Stiffness, Sugar-Sweetened Beverages and Fruits Intake in a Rural Population Sample: Data from the Brisighella Heart Study. Nutrients, 2019, 11, 2674.	1.7	28
210	Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients. Current Pharmaceutical Design, 2017, 23, 1265-1272.	0.9	28
211	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2â€year study evaluation. Fundamental and Clinical Pharmacology, 2014, 28, 221-229.	1.0	27
212	Resveratrol effect on patients with nonâ€alcoholic fatty liver disease: A matter of dose and treatment length. Diabetes, Obesity and Metabolism, 2018, 20, 1798-1799.	2.2	27
213	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 907-914.	1.1	27
214	Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence. Nutrients, 2020, 12, 378.	1.7	27
215	Relative role of major risk factors for Type 2 diabetes development in the historical cohort of the Brisighella Heart Study: an 8-year follow-up. Diabetic Medicine, 2005, 22, 1263-1266.	1.2	26
216	Interaction between serum cholesterol levels and the renin–angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. Journal of Hypertension, 2007, 25, 2051-2057.	0.3	26

#	Article	lF	Citations
217	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertension Research, 2010, 33, 790-795.	1.5	26
218	Hemodynamic and neurohumoral profile in patients with different types of hypertension in pregnancy. Internal and Emergency Medicine, 2011, 6, 227-234.	1.0	26
219	Effects of <i>n</i> à€3 PUFA on insulin resistance after an oral fat load. European Journal of Lipid Science and Technology, 2011, 113, 950-960.	1.0	26
220	Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2013, 8, 265-267.	1.0	26
221	Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. Therapeutics and Clinical Risk Management, 2016, 12, 281.	0.9	26
222	Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. Advances in Therapy, 2017, 34, 1966-1975.	1.3	26
223	Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids in Health and Disease, 2019, 18, 88.	1.2	26
224	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
225	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports, 2020, 22, 18.	2.0	26
226	Activity and potential role of licofelone in the management of osteoarthritis. Clinical Interventions in Aging, 2007, 2, 73-79.	1.3	26
227	Hypertension and Dyslipidemia Combined Therapeutic Approaches. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 221-230.	1.0	26
228	Long-term Effect of Glimepiride and Rosiglitazone on Non-conventional Cardiovascular Risk Factors in Metformin-treated Patients Affected by Metabolic Syndrome: A Randomized, Double-blind Clinical Trial. Journal of International Medical Research, 2005, 33, 284-294.	0.4	25
229	Candesartan effect on inflammation in hypertension. Hypertension Research, 2010, 33, 209-213.	1.5	25
230	Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample. Journal of Hypertension, 2012, 30, 492-496.	0.3	25
231	Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study. Metabolic Syndrome and Related Disorders, 2013, 11, 412-416.	0.5	25
232	Effect of Lactotripeptides (Isoleucine–Proline–Proline/Valine–Proline–Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial. Metabolic Syndrome and Related Disorders, 2016, 14, 161-166.	0.5	25
233	Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Internal and Emergency Medicine, 2019, 14, 949-956.	1.0	25
234	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvascular Research, 2010, 79, 144-149.	1.1	24

#	Article	IF	CITATIONS
235	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opinion on Pharmacotherapy, 2012, 13, 2581-2591.	0.9	24
236	Evidence of Clinically Relevant Efficacy for Dietary Supplements and Nutraceuticals. Current Hypertension Reports, 2013, 15, 260-267.	1.5	24
237	Long-term Effect of a Dietary Education Program on Postmenopausal Cardiovascular Risk and Metabolic Syndrome: The Brisighella Heart Study. Journal of Women's Health, 2010, 19, 133-137.	1.5	23
238	Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clinical and Experimental Hypertension, 2012, 34, 113-117.	0.5	23
239	Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2014, 9, 655-660.	1.0	23
240	Effect of spontaneous changes in dietary components and lipoprotein(a) levels: Data from the Brisighella Heart Study. Atherosclerosis, 2017, 262, 202-204.	0.4	23
241	Polyphenols Effect on Circulating Lipids and Lipoproteins: From Biochemistry to Clinical Evidence. Current Pharmaceutical Design, 2018, 24, 178-190.	0.9	23
242	Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. International Journal of COPD, 2019, Volume 14, 2733-2744.	0.9	23
243	Effects of a new low dose soy protein/?-sitosterol association on plasma lipid levels and oxidation. European Journal of Nutrition, 2004, 43, 319-322.	1.8	22
244	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial. Clinical Therapeutics, 2007, 29, 602-610.	1.1	22
245	Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 267-276.	0.7	22
246	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism: Clinical and Experimental, 2009, 58, 1059-1066.	1.5	22
247	Effects of treatment strategy on endothelial function. Autoimmunity Reviews, 2010, 9, 840-844.	2.5	22
248	Tinnitus in elderly patients and prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up. BMC Medicine, 2011, 9, 80.	2.3	22
249	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and \hat{l}^2 -cell function. Expert Opinion on Pharmacotherapy, 2012, 13, 2433-2442.	0.9	22
250	Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutrition Journal, 2015, 14, 30.	1.5	22
251	Potential Benefits of Berberine in the Management of Perimenopausal Syndrome. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-9.	1.9	22
252	Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 13-18.	1.0	22

#	Article	IF	Citations
253	Food and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up?. Trends in Food Science and Technology, 2017, 69, 192-202.	7.8	22
254	Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomedicine and Pharmacotherapy, 2005, 59, 312-317.	2.5	21
255	Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly. Drugs and Aging, 2005, 22, 393-403.	1.3	21
256	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomedicine and Pharmacotherapy, 2009, 63, 723-733.	2.5	21
257	Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 283-288.	1.0	21
258	Mast cell tryptase – Marker and maker of cardiovascular diseases. , 2019, 199, 91-110.		21
259	Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: A possible role for the coenzyme Q10?. BioFactors, 2005, 23, 7-14.	2.6	20
260	Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease: Response to Beishuizen et al Diabetes Care, 2005, 28, 1262-1263.	4.3	20
261	Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. Journal of International Medical Research, 2006, 34, 545-555.	0.4	20
262	Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naieve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial. Internal Medicine, 2007, 46, 1837-1846.	0.3	20
263	Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. Expert Opinion on Biological Therapy, 2014, 14, 863-868.	1.4	20
264	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	1.0	20
265	Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. Pharmacotherapy, 2005, 25, 637-645.	1.2	19
266	Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin. Archives of Medical Research, 2008, 39, 412-419.	1.5	19
267	Hemodynamic Effects of Lactotripeptides from Casein Hydrolysate in Mediterranean Normotensive Subjects and Patients with High-Normal Blood Pressure: A Randomized, Double-Blind, Crossover Clinical Trial. Journal of Medicinal Food, 2010, 13, 1363-1368.	0.8	19
268	Effect of a combined nutraceutical containing Orthosiphon stamineus effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: A randomized clinical trial. Complementary Therapies in Clinical Practice, 2012, 18, 190-194.	0.7	19
269	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. Canadian Journal of Physiology and Pharmacology, 2013, 91, 724-732.	0.7	19
270	Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Design, Development and Therapy, 2015, 9, 3073.	2.0	19

#	Article	IF	Citations
271	Cardiometabolic Risks and Obesity in the Young. New England Journal of Medicine, 2016, 374, 591-593.	13.9	19
272	An update on the safety of nutraceuticals and effects on lipid parameters. Expert Opinion on Drug Safety, 2018, 17, 303-313.	1.0	19
273	Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. American Journal of Cardiology, 2019, 123, 588-591.	0.7	19
274	Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. Archives of Medical Science, 2021, 17, 856-863.	0.4	19
275	Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3305-3313.	1.1	19
276	Persistence on Treatment and Blood Pressure Control with Different First-Line Antihypertensive Treatments: A Prospective Evaluation. Clinical and Experimental Hypertension, 2007, 29, 553-562.	0.5	18
277	Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription?. Mediterranean Journal of Nutrition and Metabolism, 2008, 1, 85-93.	0.2	18
278	Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutrition and Dietary Supplements, 2009, Volume 1, 1-10.	0.7	18
279	Serum <scp>LDL</scp> cholesterol levels and new onset of arterial hypertension: an 8â€year followâ€up. European Journal of Clinical Investigation, 2014, 44, 926-932.	1.7	18
280	Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 527-529.	1.1	18
281	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	0.9	18
282	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	1.1	18
283	Effect of Sulodexide on Albuminuria, NAG Excretion and Glomerular Filtration Response to Dopamine in Diabetic Patients. American Journal of Nephrology, 2006, 26, 621-628.	1.4	17
284	Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vascular Health and Risk Management, 2008, Volume 4, 665-671.	1.0	17
285	Nateglinide and glibenclamide metabolic effects in na \tilde{A} -ve type 2 diabetic patients treated with metformin. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 13-23.	0.7	17
286	The severity of coronary atherosclerosis in diabetic and non-diabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. Acta Diabetologica, 2011, 48, 21-27.	1.2	17
287	Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecological Endocrinology, 2012, 28, 699-702.	0.7	17
288	A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study. Diabetes Technology and Therapeutics, 2013, 15, 214-222.	2.4	17

#	Article	IF	CITATIONS
289	Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: A 12-years follow-up of the Brisighella Heart Study historical cohort. Diabetes Research and Clinical Practice, 2014, 104, 183-188.	1.1	17
290	Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability. Clinical Lipidology, 2015, 10, 1-4.	0.4	17
291	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. Journal of Medicinal Food, 2015, 18, 1270-1273.	0.8	17
292	Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Current Medical Research and Opinion, 2016, 32, 1633-1638.	0.9	17
293	Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2019, 293, 193-196.	0.8	17
294	Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Current Medical Research and Opinion, 2019, 35, 9-12.	0.9	17
295	Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites, 2020, 10, 428.	1.3	17
296	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	3.1	17
297	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 2020, 21, 531-539.	0.9	17
298	Advances in Technologies for Highly Active Omega-3 Fatty Acids from Krill Oil: Clinical Applications. Marine Drugs, 2021, 19, 306.	2.2	17
299	A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels. Current Medicinal Chemistry, 2016, 23, 4490-4503.	1.2	17
300	Red Yeast Rice and Statin-Intolerant Patients. American Journal of Cardiology, 2010, 105, 1504.	0.7	16
301	Kidney disease and inner ear impairment: a simpler and closer pathogenic analogy?. Internal and Emergency Medicine, 2012, 7, 93-95.	1.0	16
302	Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. Annals of Medicine, 2014, 46, 97-102.	1.5	16
303	Independent Determinants of Maternal and Fetal Outcomes in a Sample of Pregnant Outpatients With Normal Blood Pressure, Chronic Hypertension, Gestational Hypertension, and Preeclampsia. Journal of Clinical Hypertension, 2015, 17, 777-782.	1.0	16
304	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1099-1104.	1.5	16
305	Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials. Journal of the American Society of Hypertension, 2018, 12, 80-96.	2.3	16
306	Sublingual Delivery of Astaxanthin through a Novel Ascorbyl Palmitate-Based Nanoemulsion: Preliminary Data. Marine Drugs, 2019, 17, 508.	2.2	16

#	Article	IF	CITATIONS
307	Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2019, 24, 63-69.	1.0	16
308	<i>Ascophyllum nodosum</i> and <i>Fucus vesiculosus</i> on glycemic status and on endothelial damage markers in dysglicemic patients. Phytotherapy Research, 2019, 33, 791-797.	2.8	16
309	Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Annals of Medicine, 2021, 53, 1228-1243.	1.5	16
310	Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clinical Drug Investigation, 2010, 30, 843-854.	1.1	15
311	Relationship Between Serum Uric Acid and Electrocardiographic Alterations in a Large Sample of General Population: Data From the Brisighella Heart Study. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 129-134.	1.0	15
312	Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk?. International Journal of Cardiology, 2018, 250, 62-63.	0.8	15
313	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. Critical Reviews in Food Science and Nutrition, 2019, 59, 328-335.	5.4	15
314	Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Nutrients, 2021, 13, 638.	1.7	15
315	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	1.1	15
316	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism: Clinical and Experimental, 2008, 57, 1552-1557.	1.5	14
317	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 698-704.	3.1	14
318	Increasing Diagnosis of Thyroid Papillary Carcinoma Follicular Variant in South-East Anatolian Region: Comparison of Characteristics of Classical Papillary and Follicular Variant Thyroid Cancers. Endocrine Pathology, 2012, 23, 157-160.	5.2	14
319	Do we need â€`new' omega-3 polyunsaturated fatty acids formulations?. Expert Opinion on Pharmacotherapy, 2015, 16, 285-288.	0.9	14
320	Short-Term Hemodynamic Effects of Modern Wheat Products Substitution in Diet with Ancient Wheat Products: A Cross-Over, Randomized Clinical Trial. Nutrients, 2018, 10, 1666.	1.7	14
321	Pathophysiological mechanisms of statinâ€associated myopathies: possible role of the ubiquitinâ€proteasome system. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1177-1186.	2.9	14
322	Application of the Sampson equation to estimate LDL-C in children: Comparison with LDL direct measurement and Friedewald equation in the BLIP study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1911-1915.	1.1	14
323	Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm. Current Medicinal Chemistry, 2021, 28, 8595-8607.	1.2	14
324	Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control in Patients with Impaired Glucose Tolerance. Clinical Drug Investigation, 2006, 26, 529-539.	1.1	13

#	Article	IF	Citations
325	Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Longâ€term Evaluation trial. Fundamental and Clinical Pharmacology, 2009, 23, 641-648.	1.0	13
326	Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort. Obesity Facts, 2012, 5, 319-326.	1.6	13
327	Association between self-reported snoring and arterial stiffness: data from the Brisighella Heart Study. Internal and Emergency Medicine, 2016, 11, 77-83.	1.0	13
328	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 9-15.	1.5	13
329	The Gut Microbiota and Vascular Aging: A State-of-the-Art and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 3557.	1.0	13
330	Metalloproteinases in Diabetics and Nondiabetics during Acute Coronary Syndromes and after 3 Months. Endothelium: Journal of Endothelial Cell Research, 2007, 14, 175-183.	1.7	12
331	Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine. Internal Medicine, 2009, 48, 265-271.	0.3	12
332	Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. International Journal of Nephrology and Renovascular Disease, 2010, 3, 99.	0.8	12
333	The Role of Irbesartan in the Treatment of Patients with Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 19-31.	1.0	12
334	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and βâ€cell function: the triple oral therapy. Diabetic Medicine, 2013, 30, 846-854.	1.2	12
335	Inner ear symptoms: can we use them to approach cardiovascular diseases?. Internal and Emergency Medicine, 2014, 9, 825-827.	1.0	12
336	A systematic review and meta-analysis of the effect of curcuminoids on adiponectin levels. Obesity Research and Clinical Practice, 2019, 13, 340-344.	0.8	12
337	Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. European Journal of Preventive Cardiology, 2020, 27, 2251-2254.	0.8	12
338	Is the 2020 Sampson equation the best formula for LDL-C estimation?. European Journal of Internal Medicine, 2021, 83, 99-101.	1.0	12
339	Lipid-lowering nutraceuticals update on scientific evidence. Journal of Cardiovascular Medicine, 2020, 21, 845-859.	0.6	12
340	The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. Journal of Hypertension, 2022, 40, 704-711.	0.3	12
341	Recent evidence of the role of omega-3 polyunsaturated fatty acids on blood pressure control and hypertension-related complications. Future Lipidology, 2006, 1, 569-577.	0.5	11
342	Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 378.	0.9	11

#	Article	IF	CITATIONS
343	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 592-601.	0.7	11
344	Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study. International Journal of Endocrinology, 2011, 2011, 1-6.	0.6	11
345	Berberine and Monacolin Effects on the Cardiovascular Risk Profile of Women with Oestroprogestin-Induced Hypercholesterolemia. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 221-226.	1.0	11
346	Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. Atherosclerosis, 2014, 235, 81-83.	0.4	11
347	A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension. Drugs, 2018, 78, 1783-1790.	4.9	11
348	Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1031-1038.	1.5	11
349	Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Heart International, 2006, 2, 98.	0.4	11
350	Effect of Dietary Supplementation with Eufortyn® Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolemia: The ANEMONE Study. Nutrients, 2022, 14, 2099.	1.7	11
351	Metabolic syndrome prevalence in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, e5-e6.	1.1	10
352	Effects of Insulin Therapy with Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Patients: Comparison with Multi-daily Insulin Injections Therapy (MDI). Endocrine Journal, 2009, 56, 571-578.	0.7	10
353	Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Archives of Medical Science, 2010, 4, 469-477.	0.4	10
354	Predictors of the Short-Term Effect of Isoleucine–Proline–Proline/Valine–Proline–Proline Lactotripeptides from Casein on Office and Ambulatory Blood Pressure in Subjects with Pharmacologically Untreated High-Normal Blood Pressure or First-Degree Hypertension. Clinical and Experimental Hypertension, 2012, 34, 601-605.	0.5	10
355	Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients. Nutrafoods, 2012, 11, 55-61.	0.5	10
356	Combined Nutraceutical Approach to Postmenopausal Syndrome and Vascular Remodeling Biomarkers. Journal of Alternative and Complementary Medicine, 2013, 19, 582-587.	2.1	10
357	Orthorexia prevalence among health care professionals involved in nutrition education: The ADI-O Study. Mediterranean Journal of Nutrition and Metabolism, 2015, 8, 199-204.	0.2	10
358	Emerging biologic therapies for hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 1077-1087.	1.4	10
359	Prevalent Seasoning and Cooking Fats, Arterial Stiffness and Blood Lipid Pattern in a Rural Population Sample: Data from the Brisighella Heart Study. Nutrients, 2020, 12, 3063.	1.7	10
360	A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO®) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study). Nutrients, 2020, 12, 3127.	1.7	10

#	Article	IF	Citations
361	Long-Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. Journal of Clinical Medicine, 2021, 10, 5921.	1.0	10
362	Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension. Journal of Cardiovascular Pharmacology, 2006, 47, 508-512.	0.8	9
363	Effect of Zofenopril and Ramipril on Cardiovascular Mortality in Patients With Chronic Heart Failure. American Journal of Cardiology, 2013, 112, 90-93.	0.7	9
364	Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction. Journal of Hypertension, 2013, 31, 1256-1264.	0.3	9
365	Nutraceuticals and cholesterol-lowering action. IJC Metabolic & Endocrine, 2015, 6, 1-4.	0.5	9
366	Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. International Journal of Molecular Sciences, 2018, 19, 49.	1.8	9
367	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	0.8	9
368	Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials. Current Drug Metabolism, 2018, 19, 460-468.	0.7	9
369	Effect of a Lipid-Lowering Nutraceutical on Pulse-Wave-Velocity in Hypercholesterolemic Patients with or without Chronic Kidney Disease. Open Hypertension Journal, 2013, 5, 18-22.	0.8	9
370	Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart study. Journal of Endocrinological Investigation, 2011, 34, e158-62.	1.8	9
371	Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella heart study. Advances in Clinical and Experimental Medicine, 2013, 22, 69-76.	0.6	9
372	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	1.0	9
373	A suggestion for familial hypercholesterolemia (FH) heterozygosity clinical diagnosis based on epidemiological observations in a large Italian population. International Journal of Cardiology, 2000, 74, 5-11.	0.8	8
374	Cerebrovascular Disease in Italy and Europe: It Is Necessary to Prevent a â€~Pandemia'. Gerontology, 2003, 49, 69-79.	1.4	8
375	Adverse reactions related to drugs for headache treatment: clinical impact. European Journal of Clinical Pharmacology, 2005, 60, 893-900.	0.8	8
376	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. Blood Pressure, 2009, 18, 111-116.	0.7	8
377	Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 512-518.	1.1	8
378	Retargeting the management of hypercholesterolemia – focus on evolocumab. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1365-1376.	0.9	8

#	Article	IF	CITATIONS
379	Lipomatrix: A Novel Ascorbyl Palmitate-Based Lipid Matrix to Enhancing Enteric Absorption of Serenoa Repens Oil. International Journal of Molecular Sciences, 2019, 20, 669.	1.8	8
380	Misinterpreting data in lipidology in the era of COVID-19. Journal of Clinical Lipidology, 2020, 14, 543-544.	0.6	8
381	Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients. Expert Opinion on Drug Safety, 2020, 19, 1577-1583.	1.0	8
382	Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials. Marine Drugs, 2020, 18, 292.	2.2	8
383	Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients. Journal of Human Hypertension, 2003, 17, 433-435.	1.0	7
384	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 149-151.	1.5	7
385	Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. Clinical Lipidology, 2010, 5, 329-337.	0.4	7
386	Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 239-246.	0.2	7
387	Factors Associated With Increased Carotid Intima-Media Thickness and Being Nondipper in Nonobese and Normotensive Young Patients Affected by PCOS. Angiology, 2011, 62, 543-548.	0.8	7
388	Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients. Clinical and Experimental Hypertension, 2013, 35, 301-307.	0.5	7
389	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opinion on Drug Safety, 2013, 12, 621-629.	1.0	7
390	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. Archives of Medical Science, 2013, 2, 238-242.	0.4	7
391	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. Internal and Emergency Medicine, 2015, 10, 943-954.	1.0	7
392	NoSAS score associated with arterial stiffness in a large cohort of healthy individuals. Lancet Respiratory Medicine, the, 2016, 4, e54.	5.2	7
393	Gene targeting for chylomicronemia syndrome: The brave new world. Atherosclerosis, 2018, 269, 254-255.	0.4	7
394	Association Between Plasma Trans-Fatty Acid Concentrations and Measures of Glucose Homeostasis and Cardiovascular Risk Factors in Adults in NHANES 1999-2000. Angiology, 2018, 69, 630-637.	0.8	7
395	Is it Possible to Significantly Modify Blood Pressure with a Combined Nutraceutical on Top of a Healthy Diet? The Results of a Pilot Clinical Trial. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 401-405.	1.0	7
396	Uric acid and early prevention of vascular diseases: Women under the looking glass. International Journal of Cardiology, 2018, 272, 314-315.	0.8	7

#	Article	IF	Citations
397	Improvement of Executive Function after Short-Term Administration of an Antioxidants Mix Containing Bacopa, Lycopene, Astaxanthin and Vitamin B12: The BLAtwelve Study. Nutrients, 2021, 13, 56.	1.7	7
398	Serum uric acid and markers of low-density lipoprotein oxidation in nonsmoking healthy subjects: data from the Brisighella Heart Study. Polish Archives of Internal Medicine, 2014, 124, 661-668.	0.3	7
399	Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. American Heart Journal Plus, 2022, 13, 100127.	0.3	7
400	Effect of statins on the plasma/serum levels of inflammatory markers in patients with cardiovascular disease; a systematic review and meta-analysis of randomized clinical trials. Inflammopharmacology, 2022, 30, 369-383.	1.9	7
401	Detection of familial combined hyperlipoproteinaemia patients in the Brisighella Heart Study historical cohort: An epidemiological approach. Journal of Inherited Metabolic Disease, 2007, 30, 268-268.	1.7	6
402	Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statinâ€treated hypertensive hypercholesterolemic patients. Fundamental and Clinical Pharmacology, 2009, 23, 583-588.	1.0	6
403	Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension. Current Vascular Pharmacology, 2009, 7, 120-136.	0.8	6
404	Hypertension: management perspectives. Expert Opinion on Pharmacotherapy, 2012, 13, 1999-2003.	0.9	6
405	Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. Journal of Human Hypertension, 2015, 29, 409-416.	1.0	6
406	Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 205-209.	1.5	6
407	Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study. BMC Cardiovascular Disorders, 2019, 19, 20.	0.7	6
408	Highly Active Cranberry's Polyphenolic Fraction: New Advances in Processing and Clinical Applications. Nutrients, 2021, 13, 2546.	1.7	6
409	Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. World Journal of Gastroenterology, 2015, 21, 3912.	1.4	6
410	Representativity of women and racial/ethnic minorities in randomized clinical trials on bempedoic acid: Positive efforts and lacking data. European Journal of Internal Medicine, 2021, , .	1.0	6
411	New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story. European Journal of Preventive Cardiology, 2022, 29, 842-843.	0.8	6
412	Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. Journal of Clinical Medicine, 2022, 11, 219.	1.0	6
413	Complementary and Alternative Medicine for Hypertension. Evidence - Based Integrative Medicine, 2005, 2, 47-55.	0.2	5
414	Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials. Current Clinical Pharmacology, 2006, 1, 21-33.	0.2	5

#	Article	IF	Citations
415	Plasma lipid effects of corn oil and extra-virgin olive oil in hypercholesterolaemic subjects: a randomised, controlled trial. Mediterranean Journal of Nutrition and Metabolism, 2009, 1, 187-192.	0.2	5
416	Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?. Clinical Lipidology, 2012, 7, 549-559.	0.4	5
417	Are there mild and serious metabolic syndromes? The need for a graded diagnosis. Journal of Cardiovascular Medicine, 2014, 15, 759-760.	0.6	5
418	Combination therapy in the extended cardiovascular continuum. Journal of Cardiovascular Medicine, 2015, 16, 390-399.	0.6	5
419	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clinical Hypertension, 2017, 23, 10.	0.7	5
420	Commentary to: "The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trialsâ€∙ High Blood Pressure and Cardiovascular Prevention, 2018, 25, 51-52.	1.0	5
421	Questioning the Associations of I‰-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 2018, 3, 780.	3.0	5
422	Resveratrol for High Blood Pressure: A Total Failure or the Need to Identify the Right Patient?. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 421-423.	1.0	5
423	Lifestyle interventions and nutraceuticals: Guideline-based approach to cardiovascular disease prevention. Atherosclerosis: X, 2019, 1, 100003.	0.0	5
424	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. Angiology, 2020, 71, 217-225.	0.8	5
425	Laboratory and Instrumental Risk Factors Associated with a Sudden Cardiac Death Prone ECG Pattern in the General Population: Data from the Brisighella Heart Study. Journal of Clinical Medicine, 2021, 10, 640.	1.0	5
426	Diets, Foods and Food Components' Effect on Dyslipidemia. Nutrients, 2021, 13, 741.	1.7	5
427	Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients. Biomedicines, 2022, 10, 424.	1.4	5
428	Noninvasive instrumental evaluation of coenzyme <scp> Q ₁₀ </scp> phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A doubleâ€blind, randomized, placeboâ€controlled crossover clinical trial. BioFactors, 2022, , .	2.6	5
429	Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study. Biomedicines, 2022, 10, 656.	1.4	5
430	Blood Pressure Modulating Properties of Omega-3 Polyunsaturated Fatty Acids (PUFA). High Blood Pressure and Cardiovascular Prevention, 2007, 14, 55-61.	1.0	4
431	Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription?. Mediterranean Journal of Nutrition and Metabolism, 2008, 1, 85-93.	0.2	4
432	Plasma lipid effects of corn oil and extra-virgin olive oil in hypercholesterolaemic subjects: a randomised, controlled trial. Mediterranean Journal of Nutrition and Metabolism, 2009, 1, 187-192.	0.2	4

#	Article	IF	Citations
433	Weight loss and blood pressure normalization: the relevance of early interventions in hypertension. Hypertension Research, 2010, 33, 195-196.	1.5	4
434	Hypertension and diabetes incidence: confounding factors. Hypertension Research, 2011, 34, 1069-1070.	1.5	4
435	Population Health Needs Assessment and Healthcare Services Use in a 3ÂYears Follow-Up on Administrative and Clinical Data: Results from the Brisighella Heart Study. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 45-51.	1.0	4
436	New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation. Journal of Hypertension, 2017, 35, 689-695.	0.3	4
437	Canrenone on cardiovascular mortality in congestive heart failure. Pharmacological Research, 2019, 141, 46-52.	3.1	4
438	Cost-effectiveness analysis of different hypertension management strategies. Internal and Emergency Medicine, 2020, 15, 181-182.	1.0	4
439	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.0	4
440	Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Diseases (Basel, Switzerland), 2020, 8, 26.	1.0	4
441	Long-term consequences of previous preeclampsia and complicated pregnancy: analysis of echocardiographic aspects. Journal of Cardiovascular Medicine, 2021, 22, 939-945.	0.6	4
442	Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vascular Health and Risk Management, 2006, 2, 341-349.	1.0	4
443	Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 239-246.	0.2	4
444	Serum Lipopotein (a) Levels in a Large Sample of Subjects Affected by Familial Combined Hyperlipoproteinaemia and in General Population. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 149-151.	3.1	3
445	It Is Necessary to Prevent a Cerebrovascular †Pandemia'. Cerebrovascular Diseases, 2003, 15, 152-153.	0.8	3
446	Effect of oral chronic iso?avones supplementation on male rat sexual performances and sexual hormone plasma levels. Phytotherapy Research, 2004, 18, 849-852.	2.8	3
447	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy: Open Access in Clinical Medicine, 2006, 3, 733-749.	0.2	3
448	Changes in peak systolic velocity induced by chronic therapy with phosphodiesterase type-5 inhibitor. Andrologia, 2006, 38, 84-86.	1.0	3
449	Sources Of Variability Of Plasma HDL-Cholesterol Levels. Future Lipidology, 2007, 2, 557-569.	0.5	3
450	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterranean Journal of Nutrition and Metabolism, 2008, 1, 33-36.	0.2	3

#	Article	IF	CITATIONS
451	The relationship between calcium metabolism, insulin-like growth factor-1 and pulse pressure in normotensive, normolipidaemic and non-diabetic patients. Archives of Medical Science, 2011, 5, 776-780.	0.4	3
452	Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. ClinicoEconomics and Outcomes Research, 2013, 5, 317.	0.7	3
453	The possible role of Vicorder \hat{A}^{\otimes} apparatus in the diagnostic protocol of inner ear diseases. Hearing, Balance and Communication, 2015, 13, 175-177.	0.1	3
454	Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. Open Heart, 2015, 2, e000195.	0.9	3
455	The cost–effectiveness of irbesartan for hypertension. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 199-207.	0.7	3
456	Cardiovascular risk factors and hearing impairment: a non-automatic correlation. Hearing, Balance and Communication, 2016, 14, 183-188.	0.1	3
457	Successful treatment of a patient with mitochondrial myopathy with alirocumab. Journal of Clinical Lipidology, 2020, 14, 646-648.	0.6	3
458	Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. European Journal of Integrative Medicine, 2020, 37, 101164.	0.8	3
459	Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 346-351.	1.4	3
460	Humankind versus Virus: Are we winning the battle but losing the war?. Mediterranean Journal of Nutrition and Metabolism, 2020, 13, 1-5.	0.2	3
461	A double-blind, placebo-controlled clinical trial to assess the effects of a combined nutraceutical on endothelial function in patients with mild-to-moderate hypercholesterolaemia. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 36-42.	0.5	3
462	Uric acid and thrombotic risk: an emerging link. Internal and Emergency Medicine, 2020, 15, 1167-1168.	1.0	3
463	Effect of Synaid on cognitive functions and mood in elderly subjects with self-perceived loss of memory after COVID-19 infection. Archives of Medical Science, 2021, 17, 1797-1799.	0.4	3
464	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 105-113.	1.0	3
465	Triptans: the experience of a clinical pharmacologist in clinical practice. Journal of Headache and Pain, 2001, 2, s103-s106.	2.5	2
466	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 143-145.	1,5	2
467	REVERSAL and PROVE-IT: Are clinically oriented trials really better than "pure―scientific studies?. International Journal of Cardiology, 2005, 103, 235-237.	0.8	2
468	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 47-52.	1.0	2

#	Article	IF	CITATIONS
469	Global Cardiovascular Disease Risk Management in Italian Patients with Metabolic Syndrome in the Clinical Practice Setting. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 37-45.	1.0	2
470	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterranean Journal of Nutrition and Metabolism, 2008, 1, 33-36.	0.2	2
471	Increased Serum Uric Acid as a Risk Factor for Cardiovascular Diseases. Current Obesity Reports, 2013, 2, 301-305.	3.5	2
472	Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. Hearing, Balance and Communication, 2014, 12, 84-87.	0.1	2
473	LDL-oxidation, serum uric acid and pulse-wave velocity relationship in chronic kidney disease: Data from the Brisighella heart study cohort. Atherosclerosis, 2017, 263, e276.	0.4	2
474	Pericardial fat as a new independent biomarker of vascular aging. International Journal of Cardiology, 2018, 260, 211-212.	0.8	2
475	EFFECT OF RESVERATROL ON BLOOD PRESSURE. Journal of Hypertension, 2018, 36, e123.	0.3	2
476	Severe hypercholesterolaemia in a paediatric patient with congenital analbuminaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 316-317.	1.1	2
477	Are monotherapies still valuable to the treatment of hypertension?. Expert Opinion on Pharmacotherapy, 2020, 21, 1523-1526.	0.9	2
478	Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 145-151.	0.5	2
479	Statins and Nutraceuticals/Functional Food: Could They Be Combined?., 2015, , 127-142.		2
480	From classical to innovative clinical epidemiology: the 50 years' experience of the Brisighella Heart Study. Panminerva Medica, 2021, 63, .	0.2	2
481	Antihyperlipidaemic Drugs. Clinical Drug Investigation, 2000, 19, 457-464.	1.1	1
482	Cerebrovascular Disease in Italy and Europe: It is Necessary to Prevent a 'Pandemia'. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 143-145.	3.1	1
483	Application of a New Processing Method to Post-LDL-apheresis Data. Journal of Theoretical Medicine, 2002, 4, 191-196.	0.5	1
484	Asymptomatic Massive Hypertriglyceridemia in an Octogenarian. Medical Principles and Practice, 2003, 12, 51-53.	1.1	1
485	Physical activity, exercise and cardiovascular health. Future Lipidology, 2006, 1, 513-516.	0.5	1
486	Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update. Vascular Disease Prevention, 2007, 4, 229-236.	0.2	1

1

#	Article	IF	CITATIONS
487	Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years. Asian Journal of Andrology, 2009, 11, 493-497.	0.8	1
488	Effects of Telmisartan and Bisoprolol on Blood Pressure, Peripheral Haemodynamic and Lipid Profile in Statin-Treated Hypertensive Hypercholesterolaemic Patients. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 7-12.	1.0	1
489	Which statin is the ideal statin for polymedicated patients?. Clinical Lipidology, 2012, 7, 11-16.	0.4	1
490	How to avoid the depression of the adherence to antihypertensive treatment?. Journal of Hypertension, 2013, 31, 1362-1363.	0.3	1
491	Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study. European Heart Journal, 2013, 34, P3293-P3293.	1.0	1
492	Diet, dietary supplements and age-related macular degeneration (AMD). Nutrafoods, 2014, 13, 5-11.	0.5	1
493	In response: Hyperuricemia as a risk factor for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2015, 13, 21-22.	0.6	1
494	Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial. Nutrafoods, 2015, 14, 127-131.	0.5	1
495	Metabolic alterations and hearing acuity: lack of a significant clinical correlation. Hearing, Balance and Communication, 2016, 14, 91-93.	0.1	1
496	[PP.30.18] EFFECTS OF A COMBINED BLOOD PRESSURE AND LIPID-LOWERING NUTRACEUTICAL ON MILDLY HYPERTENSIVE HYPERCHOLESTEROLEMIC SUBJECTS. Journal of Hypertension, 2016, 34, e312.	0.3	1
497	Echocardiographic characteristics of hypertensive patients affected by transient ischemic attack: a cross-sectional study. Journal of the American Society of Hypertension, 2017, 11, 213-219.	2.3	1
498	Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 355-359.	1.0	1
499	Interpreting data on alpha-lipoic acid safety considering the number of subjects exposed. Clinical Nutrition, 2021, 40, 654.	2.3	1
500	Improving adherence with treatment-resistant hypertension. Expert Opinion on Pharmacotherapy, 2021, 22, 1373-1375.	0.9	1
501	Metabolic effect of berberine–silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. , 2019, 33, 862.		1
502	Clinical Case 3: Patient with Essential Hypertension and Familial Hypercholesterolaemia. Practical Case Studies in Hypertension Management, 2016, , 33-50.	0.0	1
503	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing) Tj ETQq1	1 0.784314 ı	rgBT /Over <mark>l</mark> o

504

Effect of erdosteine in moderately severe COPD patients. , 2018, , .

#	Article	IF	Citations
505	The VO2-on Kinetics in Constant Load Exercise Sub-Anaerobic Threshold Reflects Endothelial Function and Dysfunction in Muscle Microcirculation. Physiological Research, 2015, 64, 807-819.	0.4	1
506	Hypertension and hypercholesterolemia: from theory to cardiovascular disease risk prevention. Hot Topics in Cardiology, 2008, , .	0.0	1
507	Metamucil as an additional source of dietary fiber: impact of the quality of healthcare professionals' recommendations on users' experience. European Review for Medical and Pharmacological Sciences, 2015, 19, 1297-304.	0.5	1
508	Serum lipopotein (a) levels in a large sample of subjects affected by familial combined hyperlipoproteinaemia and in general population. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 149-51.	1.5	1
509	Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2246-2254.	1.1	1
510	Letter to Editor: Hypercholesterolemia underdiagnosis and undertreatment in psychiatric patients in Italy. European Journal of Epidemiology, 2002, 18, 373-374.	2.5	0
511	Clinical considerations preliminary to application of the Italian Society for the Study of Headache's guidelines regarding migraine prophylactic treatment. Journal of Headache and Pain, 2003, 4, 13-17.	2.5	0
512	Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management. Heart International, 2006, 2, 182618680600200.	0.4	0
513	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. Therapy: Open Access in Clinical Medicine, 2006, 3, 559-569.	0.2	0
514	Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study. Vascular Disease Prevention, 2007, 4, 185-189.	0.2	0
515	Survey of Endourology. Journal of Endourology, 2007, 21, 124-136.	1.1	0
516	Re: The Influence of Statin Medications on Prostate-Specific Antigen Levels. Journal of the National Cancer Institute, 2009, 101, 610-610.	3.0	0
517	Novel Mutation in the Apob Gene (Apo B-15.56): A Case Report. Balkan Journal of Medical Genetics, 2010, 13, 65-69.	0.5	0
518	Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial. Mediterranean Journal of Nutrition and Metabolism, 2011, 4, 197-201.	0.2	0
519	Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid-lowering properties: a randomized clinical trial. Mediterranean Journal of Nutrition and Metabolism, 2011, 4, 197-201.	0.2	0
520	Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients. European Heart Journal, 2013, 34, 1832-1832.	1.0	0
521	Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. Hypertension Research, 2014, 37, 492-493.	1.5	0
522	Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet…. Atherosclerosis, 2015, 243, 346-347.	0.4	0

#	Article	IF	CITATIONS
523	Metabolic approaches to antihypertensive treatment in diabetic patients. Hypertension Research, 2015, 38, 802-803.	1.5	0
524	Adjusted neck circumference and metabolic syndrome: Results from the brisighella heart study. Atherosclerosis, 2016, 252, e9.	0.4	0
525	Prognostic value of serum lipoprotein(a) levels on long-term mortality in a large sample of subjects in primary cardiovascular prevention: Data from the Brisighella Heart Study. Atherosclerosis, 2016, 252, e123-e124.	0.4	O
526	Clinical Case 2: Adult Patient with Hypertension and Diabetes. Practical Case Studies in Hypertension Management, 2016, , 17-32.	0.0	0
527	Hypertension and Metabolic Cardiovascular Risk Factors. Practical Case Studies in Hypertension Management, 2016, , .	0.0	0
528	[OP.7B.06] METABOLIC SYNDROME IN EUROPEAN RURAL POPULATION- DATA FROM THE BRISGHELLA HEART STUDY (ITALY) AND ENAH STUDY (CROATIA). Journal of Hypertension, 2016, 34, e87.	0.3	0
529	Letter by Cicero et al Regarding Article, "Long-Term Excessive Body Weight and Adult Left Ventricular Hypertrophy Are Linked Through Later-Life Body Size and Blood Pressure: The Bogalusa Heart Study― Circulation Research, 2017, 120, e50.	2.0	O
530	Circulating levels of PCSK9 and arterial stiffness in a large population sample: Data from the brisighella heart study. Atherosclerosis, 2017, 263, e105-e106.	0.4	0
531	Metabolic effects of anti-HCV direct acting antivirals (DAA): A retrospective study. Atherosclerosis, 2017, 263, e185.	0.4	0
532	[OP.1A.10] CIRCULATING LEVELS OF PCSK9 AND ARTERIAL STIFFNESS IN A LARGE POPULATION SAMPLE. Journal of Hypertension, 2017, 35, e3-e4.	0.3	0
533	[PP.25.18] EFFECT OF SPONTANEOUS CHANGES IN DIETARY COMPONENTS AND SERUM LIPOPROTEIN(A). Journal of Hypertension, 2017, 35, e301.	0.3	O
534	[PP.25.39] NUTRACEUTICAL EFFECTS ON GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH IMPAIRED FASTING GLUCOSE. Journal of Hypertension, 2017, 35, e304-e305.	0.3	0
535	[BP.11.07] LDL-OXIDATION, SERUM URIC ACID AND PULSE-WAVE VELOCITY RELATIONSHIP IN CHRONIC KIDNEY DISEASE. Journal of Hypertension, 2017, 35, e348.	0.3	O
536	Letter by Borghi and Cicero Regarding Article, "Modifiable Risk Factors and Atrial Fibrillationâ€. Circulation, 2018, 137, 1532-1533.	1.6	0
537	AN EASY STRATEGY TO MANAGE NIGHT CRAMPS ASSOCIATED TO STATIN ASSUMPTION. Journal of Hypertension, 2018, 36, e40-e41.	0.3	O
538	INTERACTION BETWEEN LDL-CHOLESTEROLEMIA, SERUM URIC LEVEL AND INCIDENT HYPERTENSION. Journal of Hypertension, 2018, 36, e228.	0.3	0
539	EFFECT OF QUANTITATIVE AND QUALITATIVE DIET PRESCRIPTION ON CHILDREN BEHAVIOUR AFTER A DIAGNOSIS OF FAMILIAL DYSLIPIDEMIA. Journal of Hypertension, 2018, 36, e252.	0.3	O
540	Portrait of the Countess Anastasia Spini (1842): acromegaly in art. Hormones, 2019, 18, 517-518.	0.9	0

#	Article	IF	Citations
541	A meta-analysis of Italian and Estonian individuals shows an effect of common variants in HMGCR on blood apoB levels. Biomarkers in Medicine, 2019, 13, 931-940.	0.6	O
542	Are we really sure about the pycnogenol antihypertensive effect?. Pharmacological Research, 2020, 151, 104543.	3.1	0
543	Food and Plant Bioactives for Reducing Cardiovascular Disease Risk. , 2021, , 237-267.		O
544	Nutraceuticals Supporting Heart Function in Heart Failure. Contemporary Cardiology, 2021, , 209-243.	0.0	0
545	Future Perspectives in Nutraceutical Research. Contemporary Cardiology, 2021, , 289-293.	0.0	O
546	Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. Medicina (Lithuania), 2021, 57, 857.	0.8	0
547	Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. Medicina (Lithuania), 2021, 57, 857.	0.8	O
548	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterranean Journal of Nutrition and Metabolism, 2009, 3, 47-54.	0.2	0
549	A Web2.0 Platform in Healthcare Created on the Basis of the Real Perceived Need of the Elderly End User. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2010, , 173-180.	0.2	O
550	Rationale for the Use of a Fixed-Dose Combination in the Management of Hypertension. Clinical Drug Investigation, 2010, , 1.	1.1	0
551	Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.7	84314 rg& T	/Overdock 10 Tf
552	VO2 Kinetics in Supra-Anaerobic Threshold Constant Tests Allow the Visualization and Quantification of the O2 Saving After Cytochrome C Oxidase Inhibition by Aerobic Training or Nitrate Administration. Physiological Research, 2013, 62, 671-679.	0.4	0
553	Serum Proinflammatory Chemokines in Healthy Elderly Taking or not Taking Simvastatin – Data from the Brisighella Heart Study. Advances in Clinical and Experimental Medicine, 2014, 23, 723-728.	0.6	O
554	Clinical Case 4: Patient with Essential Hypertension and Hypertriglyceridaemia. Practical Case Studies in Hypertension Management, 2016, , 51-67.	0.0	0
555	Clinical Case 6: Adult Patient with Hypertension and Gout. Practical Case Studies in Hypertension Management, 2016, , 85-102.	0.0	O
556	Effects of LTP2 peptide rich wheat products on blood pressure, endothelial reactivity and other cardiovascular risk factors: A double-blind, cross-over, randomized clinical trial. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, e15.	1.1	0
557	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. Therapy: Open Access in Clinical Medicine, 2006, 3, 559-569.	0.2	O
558	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy: Open Access in Clinical Medicine, 2006, 3, 733-749.	0.2	0

#	Article	ΙF	CITATIONS
559	Title is missing!. , 2020, 17, e1003121.		О
560	Title is missing!. , 2020, 17, e1003121.		0
561	Title is missing!. , 2020, 17, e1003121.		O
562	Reply - Seek methodological rigor & Deware of imitations. Clinical Nutrition, 2022, , .	2.3	0
563	A case of liver injury during lipidâ€lowering therapy. Phytotherapy Research, 2022, 36, 4017-4019.	2.8	O
564	Dietary integration with chondroitin sulfate/glucosamine hydrochloride in osteoarthritis: a critical review of available evidence. Minerva Orthopedics, 2022, 73, .	0.1	0